Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 4Neoplasm Metastasis 2Lymphatic Abnormalities 2Lymphangioma, Cystic 2Lymphangioma 2Vascular Malformations 1Solid Tumor 1Skin Diseases, Vascular 1Ovarian Neoplasms 1Neoplasms 1Meningioma 1Melanoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Arteriovenous Malformations 1

Interventions

Injections 6Fluorodeoxyglucose F18 4Cyclophosphamide 4Bevacizumab 4toripalimab 3fludarabine 2Specimen Handling 2Nivolumab 2zimberelimab 1tumor-cells apoptosis factor, human 1trametinib 1tislelizumab 1temsirolimus 1spartalizumab 1pembrolizumab 1pazopanib 1palbociclib 1olaparib 1lenvatinib 1etoposide phosphate 1enzalutamide 1envafolimab 1donafenib 1disitamab vedotin 1dabrafenib 1cemiplimab 1avelumab 1atezolizumab 1anlotinib 1WW Domain-Containing Oxidoreductase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Solid Tumor × Alpelisib × Clear all
NCT06739395 2024-12-18

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

Tianjin Medical University Second Hospital

Phase 2 Recruiting
300 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡